Loading...
XSHG
603108
Market cap795mUSD
Jul 09, Last price  
8.93CNY
1D
0.11%
1Q
-30.07%
Jan 2017
-47.41%
IPO
78.96%
Name

Shanghai Runda Medical Technology Co Ltd

Chart & Performance

D1W1MN
XSHG:603108 chart
P/E
P/S
0.77
EPS
Div Yield, %
0.34%
Shrs. gr., 5y
0.82%
Rev. gr., 5y
-0.26%
Revenues
6.98b
-16.05%
631,452,386772,338,8321,025,889,5251,358,503,3221,628,641,8682,164,688,8404,318,809,8405,964,339,2237,051,950,1827,069,156,2898,860,108,02610,494,418,6939,147,372,7198,311,780,3556,977,711,007
Net income
-548m
L
54,495,55558,794,70967,940,01575,162,10991,760,323116,427,776219,186,711261,953,799309,509,507329,981,169380,229,139417,746,459273,296,49855,280,612-548,393,978
CFO
692m
+7.01%
23,374,09338,700,97231,623,69036,114,224000538,902,960246,678,613323,441,186371,112,6900801,750,549646,947,379692,303,171
Dividend
Jul 18, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shanghai Runda Medical Technology Co., Ltd. delivers a comprehensive array of integrated medical laboratory solutions throughout China. The company's extensive offerings cover vital operational aspects for laboratories, including the provision of essential platforms, expert design and refurbishment services for facilities, the establishment of standardization protocols, and the implementation of advanced information management systems. Furthermore, Shanghai Runda supports healthcare professionals by providing medical solutions for critical diagnostic fields such as biochemistry, diabetes, Point-of-Care Testing (POCT), immunoassay analysis, and molecular biology. Alongside these, they also furnish professional technical assistance and efficient logistical services. Established in 1999, the firm is headquartered in Shanghai, China.
IPO date
May 27, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT